Patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve have similar 10-year clinical outcomes and mortality rates versus surgery, and patients with AS undergoing TAVR with the SAPIEN XT prosthesis have lower survival rates versus surgery, long-term data from randomized clinical trials show.